Plain-English translation of NCT06288373 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial compares two different treatment approaches for locally advanced cervical cancer. One group receives chemotherapy combined with an immunotherapy drug called , followed by surgery. The other group receives the standard treatment: radiation therapy combined with chemotherapy. Researchers want to see if this medication combined with chemotherapy and surgery can help more patients avoid the side effects of radiation while achieving similar or better outcomes.
Current radiation-based treatment works for many patients, but about one in four still experiences cancer recurrence or spread, and radiation can significantly affect quality of life. Early studies suggest that combining chemotherapy with immunotherapy before surgery might be a gentler alternative with comparable effectiveness.
You likely qualify if…
You likely don't qualify if…
If you join the immunotherapy group, you will receive chemotherapy infusions followed by immunotherapy infusions over several weeks, then imaging tests to see how your cancer responds. If your cancer shrinks or disappears, you will have surgery to remove your uterus and lymph nodes. If your cancer does not respond well, you will switch to standard radiation treatment. The other group simply receives radiation with concurrent chemotherapy. You will have regular clinic visits, imaging scans, and blood tests throughout the trial and during follow-up to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China